15 Best Growth Stocks to Invest in for the Next 5 Years

Page 12 of 13

2. Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

Upside potential as of June 24, 2025: 521.53%

Analysts at Stifel reiterated their Buy rating on Vistagen Therapeutics, Inc. (NASDAQ:VTGN) with an unchanged price target of $12.00 post the company’s fiscal 2025 announcement. Earlier in the current quarter, the management announced that while the PAL-3 study is in the right direction to present results in the last quarter of 2025, there is a slight delay in the PAL-4 data readout to the first half of the upcoming year.

According to the management, the modest delay is associated with the use of enrollment projections from the PAL-2 study, together with the adoption of tight patient selection criteria so that the chances of success could be higher. The company noted that patient demand remains quite strong and is not attributed to this new update.

The research firm firmly believes that Vistagen Therapeutics, Inc. (NASDAQ:VTGN) has “a credible shot at success in either PAL-3/PAL-4,” which in turn would provide access to what the firm thinks is a large commercial opportunity in social anxiety disorder. Having said that, Stifel analysts maintain a “relatively low-risk, high-reward bet” on the company.

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is a California-based clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapies for neuropsychiatric and neurological disorders. The core offerings of that company, which was founded in 1998, include Fasedienol(PH94B), Itruvone(PH10), PH80, and PH284.

Page 12 of 13